Skip to main content
MedPathMedPath Home
Clinical Trials/PACTR202210522771809
PACTR202210522771809
Recruiting
未知

Association of Vascular Endothelial Growth Factor (VEGF) serum levels And Ankylosing Spondylitis in Egyptian patients

Hossam salaheldin Abdelmohsen Labib0 sites70 target enrollmentOctober 21, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAnkylosing spondylitis

Overview

Phase
未知
Intervention
Not specified
Conditions
Ankylosing spondylitis
Sponsor
Hossam salaheldin Abdelmohsen Labib
Enrollment
70
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 21, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Hossam salaheldin Abdelmohsen Labib

Eligibility Criteria

Inclusion Criteria

  • •Adult AS(ankylosing spondylitis ) patients
  • •20\-60 years old
  • •met the modified New York criteria for AS.

Exclusion Criteria

  • •Patients with any associated rheumatic diseases.
  • •\- patients with cancers.
  • •\- Diabetic patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Vascular Endothelial Growth Factor, thrombelastography and coagulation in the context of etiology, outcome and clinical course of patients after circulatory arrestI46Cardiac arrest
DRKS00033234BG-Klinikum Unfallkrankenhaus Berlin150
Completed
Not Applicable
The effect of vascular endothelial growth factor taking tube shunt for neovascular glaucomaneovascular glaucoma
JPRN-UMIN000018407Yokohama City university center hospital the department of opthalmology20
Recruiting
Phase 3
A clinical trial to study the levels of vascular endothelial growth factor in the fluid in the front part of the eye in cases of occlusion of venous supply of the eye and to correlate with the clinical features and nerve thickness as obtained by scanning and nerve function tests
CTRI/2012/12/003270arayana Nethralaya30
Completed
Not Applicable
Effect of anti-vascular endothelial growth factor (VEGF) drugs in chronic central serous chorioretinopathy (CSC)chronic central serous chorioretinopathy
JPRN-UMIN000014110Kansai medical university takii hospital10
Completed
Not Applicable
Anti-vascular endothelial growth factor therapy for ocular diseases of neovascularizatioretinopathy of prematurity neovascular glaucome vasoproliferative tumor choroidal neovascularization
JPRN-UMIN000027243School of Medicine Toho University20